Hera Therapeutics

Hera Therapeutics is a biotechnology company focused on developing novel small molecule therapeutics for the treatment of Human Papillomavirus (HPV) infections and associated malignancies. The company's primary research centers on inhibiting the HPV E6 oncoprotein, which is essential for viral persistence and the degradation of the p53 tumor suppressor protein. By targeting this mechanism, Hera aims to develop non-invasive, topical treatments for precancerous lesions such as cervical intraepithelial neoplasia (CIN). Their approach seeks to provide an alternative to surgical interventions, potentially preventing the progression of HPV infections to cervical, anal, and oropharyngeal cancers.